Sapphire 3 CTO Study
Sapphire 3 - A Prospective, Open Label, Multi-center, Single Arm, Observational Study Designed to Evaluate the Acute Safety and Device Performance of the Sapphire 3 0.85-1.25 mm Coronary Dilatation Catheter in Predilatation of Chronic Total Occlusion (CTO) Lesions During Percutaneous Coronary Intervention.
Sponsor: Avania
Listed as NCT06358508, this NA trial focuses on Arteriosclerosis and Cardiovascular Diseases and remains completed. Sponsored by Avania, it has been updated 7 times since 2024, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
7 versions recorded-
Feb 2026 — Present [monthly]
Completed NA
Status: Recruiting → Completed
-
Jul 2025 — Feb 2026 [monthly]
Recruiting NA
-
Apr 2025 — Jul 2025 [monthly]
Recruiting NA
-
Dec 2024 — Apr 2025 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Not Yet Recruiting NA
▶ Show 2 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting NA
-
May 2024 — Jul 2024 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Avania
- OrbusNeich
For direct contact, visit the study record on ClinicalTrials.gov .